We agree that information regarding long-term use of hydroxychloroquine and coronavirus disease 2019 (COVID-19) outcomes is needed. When reporting a case to the COVID-19 Global Rheumatology Alliance registry, providers are asked to report on various medications taken before the patient had COVID-19. Although specific details on individual medications might not have been included in our Comment,1 we report the percentage of cases on a number of immunomodulatory and immunosuppressive drugs, including antimalarials, on a weekly basis to our website, Twitter account, and mailing list, so these data are widely accessible and regularly updated.
We disagree with the claim that “hydroxychloroquine use might be an explanation for no report of systemic lupus erythematosus patients with COVID-19,”2 and therefore have already responded with data that disprove this statement from the COVID-19 Global Rheumatology Alliance registry.3 In this response, we provide specific details on the numbers of cases reported to the registry that were using antimalarials, and show that among systemic lupus erythematosus cases reported to our registry, we did not find differences in the frequency of COVID-19 hospitalisations between individuals using antimalarials and non-users. We also plan to investigate differences in COVID-19 outcomes by a variety of immunomodulatory and immunosuppressive medications in upcoming publications.
We appreciate the request for detailed information on cases collected in the COVID-19 Global Rheumatology Alliance registry. As the pandemic unfolds, we hope to continue to provide the latest data and information entered into the registry via different platforms, with the goal to further understanding of COVID-19 in the rheumatic disease population.
Acknowledgments
MAG is supported by the US National Institutes of Health (K01 AR070585, NIAMS). The views expressed here are those of the author and not necessarily those of the National Institutes of Health, the American College of Rheumatology, or any other organisation.
References
- 1.Gianfrancesco MA, Hyrich KL, Gossec L. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 doi: 10.1016/S2665-9913(20)30095-3. published online April 16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Joob B, Wiwanitkit V. SLE, hydroxychloroquine and no SLE patients with covid-19: a comment. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-217506. published online April 15. [DOI] [PubMed] [Google Scholar]
- 3.Konig MF, Kim AHJ, Scheetz MH, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis (in press). [DOI] [PMC free article] [PubMed]